Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5

WILMINGTON, Del. and SACRAMENTO, Calif., Aug. 27, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today announced the filing of its Second Amended Complaint naming six registered broker-dealers and two broker-dealer principals as defendants for the first time, in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC).

A copy of the Second Amended Complaint is available at https://bit.ly/45Q1MLE.

About Lunai Bioworks, Inc.

Lunai Bioworks, Inc. (Nasdaq: LNAI) is a Delaware corporation headquartered in Sacramento, California. Lunai is an AI-driven platform for precision medicine that identifies targets for new therapeutics and biodefense countermeasures. The company has developed a cancer immunotherapy for solid tumors and proprietary, patented technologies that transform complex biomedical data into predictive insights. Lunai's platforms include Augusta, an AI-powered precision neurology platform, and a portfolio focused on central nervous system disorders. The company also pursues federal government contracts in support of national security and biodefense applications through its AI platform. For more information, visit www.biosymetrics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lunai's litigation strategy, its expectations regarding the identification of additional defendants, and the anticipated outcome or recovery from the lawsuit described herein. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks inherent in civil litigation, the possibility that discovery does not develop as anticipated, that courts may not accept the legal theories advanced, that named defendants may contest the allegations, and that any recovery, if obtained, may differ materially from the amounts or outcomes described or implied in this release. The allegations described in this release are allegations only and have not been proven; defendants are presumed to have meritorious defenses unless and until a court or jury determines otherwise. Lunai undertakes no obligation to update these statements except as required by law. Investors should review Lunai's filings with the Securities and Exchange Commission for a further discussion of these and other risks.

SOURCE Lunai Bioworks Inc.